Astellas, AVEO enter development, commercialization agreement for tivozanib

[News]

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

More... (http://www.news-medical.net/news/20110217/Astellas-AVEO-enter-development-commercialization-agreement-for-tivozanib.aspx)